UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
——————————
Form 8-K
——————————
Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report: June 13, 2013
Date of earliest event reported: June 12, 2013
——————————
Warner Chilcott Public Limited Company
(Exact name of registrant as specified in its charter)
——————————
|
Ireland
|
0-53772
|
98-0626948
|
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
1 Grand Canal Square, Docklands
Dublin 2, Ireland
(Address of principal executive offices, including zip code)
+353 1 897 2000
(Registrant’s telephone number, including area code)
——————————
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
Item 8.01.
|
Other Events.
|
On June 12, 2013, the U.S. District Court for the Eastern District of Pennsylvania entered a denial, without prejudice, of Warner Chilcott Public Limited Company (the “Company”) and Mayne Pharma International Pty. Ltd.’s (“Mayne”) motions to dismiss in the Company and Mayne’s previously-disclosed DORYX antitrust litigation against Mylan Pharmaceuticals Inc. and certain purported direct and indirect purchasers of the Company’s DORYX products.
The Company intends to vigorously defend its rights in the litigations. However, it is impossible to predict with certainty the outcome of any litigation. These proceedings are in the early stages of litigation and the Company can offer no assurance as to when the lawsuits will be decided, whether the Company will be successful in its defense and whether any additional similar suits will be filed.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
WARNER CHILCOTT PUBLIC LIMITED COMPANY
|
||||
|
By:
|
/s/ Paul Herendeen | |||
| Name: | Paul Herendeen | |||
| Title: | Executive Vice President and Chief Financial Officer |
|||
Date: June 13, 2013